Brainstorm Cell Therapeutics (BCLI)
NASDAQ:BCLI

Brainstorm Cell Therapeutics (BCLI) Stock Forecast & Price Target

394 Followers
See the Price Targets and Ratings of:

BCLI Analyst Ratings

Moderate Buy
1Ratings
1 Buy
0 Hold
0 Sell
Based on 1 analysts giving stock ratings to
Brainstorm
Cell Therapeutics
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

BCLI Stock 12 Months Forecast

Average Price Target

$5.00
▲(194.12% Upside)
Based on 1 Wall Street analysts offering 12 month price targets for Brainstorm Cell Therapeutics in the last 3 months. The average price target is $5.00 with a high forecast of $5.00 and a low forecast of $5.00. The average price target represents a 194.12% change from the last price of $1.70.
Highest Price Target$5.00Average Price Target$5.00Lowest Price Target$5.00
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Upgrade Banner
Dawson James
$4.00
Hold
135.29%
Upside
Reiterated
Dawson James Maintains Brainstorm Cell Therapeutics (BCLI) at Neutral, "NurOwn Efficacy, At Best, is Minimal"Dawson James analyst Jason Kolbert reiterated a Neutral rating on Brainstorm Cell Therapeutics (NASDAQ: BCLI), following the companys Q1 report.
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
xxxxxxxxxxxxxxx
xxxxxxxxxxxxxxx
xxxxxxxxxxxxxxx
xxxxxxxxxxxxxxx
xxxxxxxxxxxxxxx
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

BCLI Financial Forecast

BCLI Earnings Forecast
Next quarter’s earnings estimate for BCLI is -$0.14 with a range of -$0.18 to -$0.11. The previous quarter’s EPS was -$0.19. BCLI beat its EPS estimate 25.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 52.54% of the time in the same period. In the last calendar year BCLI has Underperformed its overall industry.
Next quarter’s earnings estimate for BCLI is -$0.14 with a range of -$0.18 to -$0.11. The previous quarter’s EPS was -$0.19. BCLI beat its EPS estimate 25.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 52.54% of the time in the same period. In the last calendar year BCLI has Underperformed its overall industry.
No data currently available
BCLI Sales Forecast
Next quarter’s sales forecast for BCLI is $0.00 with a range of $0.00 to $0.00. The previous quarter’s sales results were $0.00. BCLI beat its sales estimates 0.00% of the time in past 12 months, while its overall industry beat sales estimates 42.85% of the time in the same period. In the last calendar year BCLI has Underperformed its overall industry.
Next quarter’s sales forecast for BCLI is $0.00 with a range of $0.00 to $0.00. The previous quarter’s sales results were $0.00. BCLI beat its sales estimates 0.00% of the time in past 12 months, while its overall industry beat sales estimates 42.85% of the time in the same period. In the last calendar year BCLI has Underperformed its overall industry.
BCLI Analyst Recommendation Trends
In the current month, BCLI has received 1 Buy ratings 0 Hold ratings, and 0 Sell ratings. The BCLI average analyst price target in the past 3 months is $5.00
In the current month, BCLI has received 1 Buy ratings 0 Hold ratings, and 0 Sell ratings. The BCLI average analyst price target in the past 3 months is $5.00

BCLI Stock Forecast FAQ

What is BCLI’s average 12-month price target, according to analysts?
Based on analyst ratings, Brainstorm Cell Therapeutics’s 12-month average price target is $5.00.
    What is BCLI’s upside potential, based on the analysts’ average price target?
    Brainstorm Cell Therapeutics has 194.12% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is BCLI a Buy, Sell or Hold?
          Brainstorm Cell Therapeutics has a conensus rating of Moderate Buy which is based on 1 buy ratings, 0 hold ratings and 0 sell ratings.
            What is Brainstorm Cell Therapeutics’s price target?
            The average price target for Brainstorm Cell Therapeutics is $5.00. This is based on 1 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst price target is $5.00 ,the lowest forecast is $5.00. The average price target represents 194.12% Increase from the current price of $1.7.
              What do analysts say about Brainstorm Cell Therapeutics?
              Brainstorm Cell Therapeutics’s analyst rating consensus is a ‘Moderate Buy. This is based on the ratings of 1 Wall Streets Analysts.

                What's Included in PREMIUM?
                Make informed decisions based on Top Analysts' activity
                Know what industry insiders are buying
                Get actionable alerts from top Wall Street Analysts
                Find out before anyone else which stock is going to shoot up
                Get powerful stock screeners & detailed portfolio analysis